Sickle cell disease: A phenotypic patchwork

Renaissance of Sickle Cell Disease Research in the Genome Era

Volumn , Issue , 2007, Pages 45-67

  Smith Whitley, Kim ^a   Pace, Betty S ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84967584839     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9781860947964_0004     Document Type: Chapter

References (111)

1. Herrick JB (1910). Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Arch Int Med 6:517-521.
2. Konotey-Ahulu FID. Effect of environment on sickle cell disease in West Africa: epidemiologic and clinical considerations. In: Sickle Cell Disease, Diagnosis, Management, Education and Research, Abramson H, Bertles JF, Wethers DL. editors. CV Mosby Co, St. Louis. 1973. 20.
3. Pauling L, Itano H, Singer SJ, Wells IC (1949). Sickle cell anemia: a molecular disease. Science 110:543.
4. Ingram VM (1957). Gene mutations in human haemoglobins: the chemical difference between normal and sickle cell haemoglobin. Nature 180:326.
5. Nagel RL, Fabry ME, Pagnier J, Zohoun I, Wajcman H, Baudin V, Labie D (1985). Hematologically and genetically distinct forms of sickle cell anemia in Africa. N Engl J Med 312:880.
6. Pagnier J, Mears JG, Dunda-Belkhodja O, Schaefer-Rego KE, Beldjord C, Nagel RL, Labie D (1984). Evidence for the multicentric origin of the sickle cell hemoglobin gene in Africa. Proc Natl Acad Sci USA 81:1771-1773.
7. Nagel RL, Fabry ME (1985). The many pathophysiologies of sickle cell anemia. Am J Hematol 20:195.
8. Kurnit DM (1979). Evolution of sickle variant gene. Lancet 1:104.
9. Carlson J, Nash GB, Gabutti V, al-Yaman F, Wahlgren M (1994). Natural protection against severe Plasmodium falciparum malaria due to impaired rosette formation. Blood 84:3909.
10. Gelpi AP, King MC (1976). Duffy blood group and malaria. Science 191:1284.
11. Friedman MJ (1994). Erythrocytic mechanism of sickle cell resistance to malaria. Proc Natl Acad Sci USA 75:1994.
12. Fleming HA (1989). Causes of ‘natural’ sudden death. BMJ 298:120.
13. Modiano D, Luoni G, Sirima BS, Lanfrancotti A, Petrarca V, Cruciani F, Simpore J, Ciminelli BM, Foglietta E, Grisanti P, Bianco I, Modiano G, Coluzzi M (2001). The lower susceptibility to Plasmodium falciparum malaria of Fulani of Burkina Faso (west Africa) is associated with low frequencies of classic malaria-resistance genes. Trans R Soc Trop Med Hyg 95:149-152.
14. Luzzi GA, Merry AH, Newbold CI, Marsh K, Pasvol G (1991). Protection by alpha-thalassaemia against Plasmodium falciparum malaria: modified surface antigen expression rather than impaired growth or cytoadherence. Immunol Let 30:233-240.
15. Roth EF Jr, Raventos-Suarez C, Rinaldi A, Nagel RL (1983). Glucose-6-phosphate dehydrogenase deficiency inhibits in vitro growth of Plasmodium falciparum. Proc Natl Acad Sci USA 80:298-299.
16. Stamatoyannopoulos G, Grosveld F (2001). Hemoglobin switching. In: Stamatoyannopoulos G, Majerus PW, Perlmutter RM, Varmus H, editors. The Molecular Basis of Blood Disease. Vol. 3. Philadelphia: Saunders.
17. Hardison RC, Chui DH, Giardine B, Riemer C, Patrinos GP, Anagnou N, Miller W, Wajcman H (2002). HbVar: a relational database of human hemoglobin variants and thalassemia mutations at the globin gene server. Hum Mutat 19:225-233.
18. Flint J, Harding RM, Boyce AJ, Clegg JB (1998). The population genetics of the haemoglobinopathies. Baillieres Clin Haematol 11:1-51.
19. Bonds DR (2005). Three decades of innovation in the management of sickle cell disease: the road to understanding the sickle cell disease clinical phenotype. Blood Rev 19:99-110.
20. FDA Prevalence SCD.
21. Aluoch JR (1995). The presence of sickle cells in the peripheral blood film. Specificity and sensitivity of diagnosis of homozygous sickle cell disease in Kenya. Trop Geogr Med 47:89-91.
22. Sickle Cell Disease Guideline Panel. Sickle Cell Disease: Screening, Diagnosis, Management, and Counseling in Newborns and Infants. Rockville, MD: Agency for Health Care Policy and Research, US Department of Health and Human Services, 1993, AHCPR Publ. No. 93-0562.
23. Sickle Cell Disease Guideline Panel. Sickle Cell Disease: Screening, Diagnosis, Management and Counseling in Newborns and Infants. Clinical Practice Guidelines no. 6, Rockville, MD: Agency for Health Care Policy and Research US Public Health Service, 1993, AHCPR Publ. No. 93-0562.
24. Nagel RL, Ranney HM (1990). Genetic epidemiology of structural mutations of the beta-globin gene. Semin Hematol 27:342-359.
25. Nagel RL, Bookchin RM (1973). Simplified automated solubility test for the detection of hemoglobin S applicable to mass screening. Am J Clin Pathol 59:300-305.
26. Old JM, Heath C, Fitches A, Thein SL, Jeffreys AJ, Petrou M, Modell B, Weatherall DJ (1986). Meiotic recombination between two polymorphic restriction sites within the beta globin gene cluster. J Med Gene 23:14-18.
27. Cheung MC, Goldberg JD, Kan YW (1996). Prenatal diagnosis of sickle cell anaemia and thalassaemia by analysis of fetal cells in maternal blood. Nat Genet 14:264-268.
28. Chiu RW, Lau TK, Leung TN, Chow KC, Chui DH, Lo YM (2002). Prenatal exclusion of beta thalassaemia major by examination of maternal plasma. Lancet 360:998-1000.
29. Kan YW, Dozy AM (1978). Polymorphism of DNA sequence adjacent to human beta-globin structural gene: relationship to sickle mutation. Proc Natl Acad Sci USA 75:5631-5635.
30. Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, Erlich HA, Arnheim N (1985). Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230:1350-1354.
31. Embury SH, Scharf SJ, Saiki RK, Gholson MA, Golbus M, Arnheim N, Erlich HA (1987). Rapid prenatal diagnosis of sickle cell anemia by a new method of DNA analysis. N Engl J Med 316:656-561.
32. Jassim N, Al-Arrayed S, Gerard N, Al-Mukharraq H, Al-Ajami A, Ramasawmy R, Krishnamoorthy R (1999). A mismatched-primer polymerase chain reaction-restriction fragment length polymorphism strategy for rapid screening of the polyadenylation signal mutation alpha(T-Saudi) (AATAAA→AATAAG) in the alpha2-globin gene. Hemoglobin 23:213-220.
33. Sanger F, Nicklen S, Coulson AR (1977). DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74:5463-5467.
34. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, Smith JC, Markham AF (18989). Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 17:2503-2516.
35. Old JM, Varawalla NY, Weatherall DJ (1990). Rapid detection and prenatal diagnosis of beta-thalassaemia: studies in Indian and Cypriot populations in the UK. Lancet 336:834-837.
36. Ye S, Dhillon S, Ke X, Collins AR, Day IN (2001). An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res 29:E88-8.
37. Faa V, Rosatelli MC, Sardu R, Meloni A, Toffoli C, Cao A (1992). A simple electrophoretic procedure for fetal diagnosis of beta-thalassaemia due to short deletions. Prenat Diagn 12:903-908.
38. Chong SS, Boehm CD, Cutting GR, Higgs DR (2000). Simplified multiplex-PCR diagnosis of common southeast asian deletional determinants of alpha-thalassemia. Clin Chem 46:1692-1695.
39. Losekoot M, Fodde R, Harteveld CL, van Heeren H, Giordano PC, Bernini LF (1990). Denaturing gradient gel electrophoresis and direct sequencing of PCR amplified genomic DNA: a rapid and reliable diagnostic approach to beta thalassaemia. Br J Haematol 76:269-274.
40. Braun A, Roth R, McGinniss MJ (2003). Technology challenges in screening single gene disorders. Eur J Pediatr 162 (Suppl 1):S13-6.
41. Daniel YA, Turner C, Haynes RM, Hunt BJ, Dalton RN (2005). Rapid and specific detection of clinically significant haemoglobinopathies using electrospray mass spectrometry-mass spectrometry. Br J Haematol 130:635-643.
42. Masood E (1999). As consortium plans free SNP map of human genome. Nature 398:545-546.
43. Syvanen AC (2005). Toward genome-wide SNP genotyping. Nat Genet 37(Suppl):S5-10.
44. Tonisson N, Kurg A, Kaasik K, Lohmussaar E, Metspalu A (2000). Unravelling genetic data by arrayed primer extension. Clin Chem Lab Med 38:165-170.
45. Warrington JA, Shah NA, Chen X, Janis M, Liu C, Kondapalli S, Reyes V, Savage MP, Zhang Z, Watts R, DeGuzman M, Berno A, Snyder J, Baid J (2002). New developments in high-throughput resequencing and variation detection using high density microarrays. Hum Mutat 19:402-409.
46. Jain KK (2005). Applications of Ampli Chiptrade mark CYP450. Mol Diagn 9:119-227.
47. Machado RF, Martyr S, Kato GJ, Barst RJ, Anthi A, Robinson MR, Hunter L, Coles W, Nichols J, Hunter C, Sachdev V, Castro O, Gladwin MT (2005). Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol 130:445-453.
48. Gaston M, Rosse WF (1982). The cooperative study of sickle cell disease: review of study design and objectives. Am J Pediatr Hematol Oncol 4:197-201.
49. Gaston M, Smith J, Gallagher D, et al. (1987). Recruitment in the Cooperative Study of Sickle Cell Disease (CSSCD). Control Clin Trials 8:131S-140S.
50. Platt OS, Thorington BD, Brambilla DJ, et al. (1991). Pain in sickle cell disease. Rates and risk factors. N Engl J Med 325:11-16.
51. Gill FM, Sleeper LA, Weiner SJ, et al. (1995). Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood 86:776-783.
52. Nolan VG, Wyszynski DF, Farrer LA, Steinberg MH (2005). Hemolysis-associated priapism in sickle cell disease. Blood 106:3264-3267.
53. Smith-Whitley K, Zhao H, Hodinka RL, et al. (2004). Epidemiology of human parvovirus B19 in children with sickle cell disease. Blood 103:422-427.
54. Castro O, Brambilla DJ, Thorington B, et al. (1994). The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 84:643-9.
55. Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson B (1997). Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood 89:1787-1792.
56. Vichinsky EP, Neumayr LD, Earles AN, et al. (2000). Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med 342:1855-1865.
57. Rucknagel DL (2001). The role of rib infarcts in the acute chest syndrome of sickle cell diseases. Pediatr Pathol Mol Med 20:137-154.
58. Sullivan KJ, Goodwin SR, Evangelist J, Moore RD, Mehta P (1999). Nitric oxide successfully used to treat acute chest syndrome of sickle cell disease in a young adolescent. Crit Care Med 27:2563-2568.
59. Sharan K, Surrey S, Ballas S, Borowski M, Devoto M, Wang KF, Sandler E, Keller M (2004). Association of T-786C eNOS gene polymorphism with increased susceptibility to acute chest syndrome in females with sickle cell disease. Br J Haematol 124:240-243.
60. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. (1998). Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 91:288-294.
61. Miller ST, Macklin EA, Pegelow CH, et al. (2001). Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr 139:385-390.
62. Adams R, McKie V, Nichols F, et al. (1992). The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med 326:605-610.
63. Adams RJ, McKie VC, Hsu L, et al. (1998). Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 339:5-11.
64. Hsu LL, Miller ST, Wright E, et al. (2003). Alpha Thalassemia is associated with decreased risk of abnormal transcranial Doppler ultrasonography in children with sickle cell anemia. J Pediatr Hematol Oncol 25:622-628.
65. Driscoll MC, Hurlet A, Styles L, et al. (2003). Stroke risk in siblings with sickle cell anemia. Blood 101:2401-2404.
66. Kwiatkowski JL, Hunter JV, Smith-Whitley K, Katz ML, Shults J, Ohene-Frempong K (2003). Transcranial Doppler ultrasonography in siblings with sickle cell disease. Br J Haematol 121:932-937.
67. Hoppe C, Klitz W, Noble J, Vigil L, Vichinsky E, Styles L (2003). Distinct HLA associations by stroke subtype in children with sickle cell anemia. Blood 101: 2865-2869.
68. Hoppe C, Klitz W, Cheng S, et al. (2004). Gene interactions and stroke risk in children with sickle cell anemia. Blood 103:2391-2396.
69. Sebastiani P, Ramoni MF, Nolan V, Baldwin CT, Steinberg MH (2005). Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet 37:435-440.
70. Wang W, Enos L, Gallagher D, Thompson R, Guarini L, Vichinsky E, Wright E, Zimmerman R, Armstrong FD (2001). In: Cooperative Study of Sickle Cell Disease. Neuropsychologic performance in school-aged children with sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr 139: 391-397.
71. Moser FG, Miller ST, Bello JA, et al. (1996). The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease. AJNR Am J Neuroradiol 17:965-972.
72. Kinney TR, Sleeper LA, Wang WC, et al. (1999). Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease. Pediatrics 103:640-645.
73. Nolan VG, Baldwin C, Ma Q, Wyszynski DF, Amirault Y, Farrell JJ, Bisbee A, Embury SH, Farrer LA, Steinberg MH (2005). Association of single nucleotide polymorphisms in klotho with priapism in sickle cell anaemia. Br J Haematol 128(2):266-272.
74. Saad ST, Lajolo C, Gilli S, Marques Junior JF, Lima CS, Costa FF, Arruda VR (2004). Follow-up of sickle cell disease patients with priapism treated by hydroxyurea. Am J Hematol 77:45-49.
75. Koshy M, Entsuah R, Koranda A, et al. (1989). Leg ulcers in patients with sickle cell disease. Blood 74:1403-1408.
76. Covitz W, Espeland M, Gallagher D, Hellenbrand W, Leff S, Talner N (1995). The heart in sickle cell anemia. The Cooperative Study of Sickle Cell Disease (CSSCD). Chest 108(5):1214-1219.
77. Platt OS, Rosenstock W, Espeland MA (1984). Influence of sickle hemoglobinopathies on growth and development. N Engl J Med 311:7-12.
78. Wang WC, Morales KH, Scher CD, et al. (2005). Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial. J Pediatr 147:244-247.
79. Leonard MB, Zemel BS, Kawchak DA, Ohene-Frempong K, Stallings VA (1998). Plasma zinc status, growth, and maturation in children with sickle cell disease. J Pediatr 132:467-471.
80. Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W (1989). Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. Pediatrics 84:500-508.
81. Platt OS, Brambilla DJ, Rosse WF, et al. (1994). Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 330:1639-1644.
82. Miller ST, Sleeper LA, Pegelow CH, et al. (2000). Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 342:83-89.
83. National Heart Lung and Blood Institute. The Management of Sickle Cell Disease, 4th edition. National Institutes of Health, 2004.
84. Charache S, Barton FB, Moore RD, et al. (1996). Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive “switching” agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore) 75:300-326.
85. Steinberg MH, Barton F, Castro O, et al. (2003). Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 289:1645-1651.
86. Miller MK, Zimmerman SA, Schultz WH, Ware RE (2001). Hydroxyurea therapy for pediatric patients with hemoglobin SC disease. J Pediatr Hematol Oncol 23:306-308.
87. Wang WC, Helms RW, Lynn HS, Redding-Lallinger R, Gee BE, Ohene-Frempong K, Smith Whitley K, Waclawiw MA, Vichinsky EP, Styles LA, Ware RE, Kinney TR (2002). Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. J Pediatr 140:225-229.
88. Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA (2004). Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 103:2039-2045.
89. Fung EB, Barden EM, Kawchak DA, Zemel BS, Ohene-Frempong K, Stallings VA (2001). Effect of hydroxyurea therapy on resting energy expenditure in children with sickle cell disease. J Pediatr Hematol Oncol 23:604-608.
90. Hankins JS, Ware RE, Rogers ZR, et al. (2005). Long-term hydroxyurea therapy for infants with sickle cell anemia - the Husoft extension study. Blood 106:2269-2275.
91. Ohene-Frempong K (2001). Indications for red cell transfusion in sickle cell disease. Semin Hematol 38:5-13.
92. Vichinsky EP, Haberkern CM, Neumayr L, et al. (1995). A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med 333(4):206-213.
93. Rosse WF, Gallagher D, Kinney TR, et al. (1990). Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood 76(7):1431-1437.
94. Newborn Screening Task Force (2000). Serving, the family from birth to the medical home. Newborn screening: a blueprint for the future-a call for a national agenda on state newborn screening programs. Pediatrics 106:383-422.
95. American Academy of Pediatrics, Committee on Practice and Ambulatory Medicine. Recommendations for preventive pediatric health care (1995). Pediatrics 96: 373-374.
96. Gaston MH, Verter JI, Woods G, et al. (1986). Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. N Engl J Med 314:1593-1599.
97. Sickle Cell Disease Guideline Panel. Sickle Cell Disease: Screening, Diagnosis, Management, and Counseling in Newborns and Infants. Rockville, MD: Agency for Health Care Policy and Research, US Department of Health and Human Services; 1993; AHCPR Publ. No. 93-0562.
98. +-thalassemia: is prophylactic penicillin necessary? J Pediatr 127:348-354.
99. Rodriquez-Cortes HM, Griener JC, Hyland K, et al. (1999). Plasma homocysteine levels and folate status in children with sickle cell anemia. J Pediatr Hematol Oncol 21:219-223.
100. American Academy of Pediatrics, Committee on Infectious Diseases (2002). Recommended childhood immunization schedule - United States, 2002. Pediatrics 109:162-164.
101. American Academy of Pediatrics, Committee on Infectious Diseases (2000). Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 106:362-366.
102. American Academy of Pediatrics (2000). Red Book: Report of the Committee on Infectious Diseases. Pickering LK editor, 25th ed. Elk Grove Village, IL: American Academy of Pediatrics.
103. Pass KA, Lane PA, Fernhoff PM, et al. (2000). US newborn screening system guidelines II: follow-up of children, diagnosis, management, and evaluation. J Pediatr 37(suppl):S1-S46.
104. Telfair J, Alexander LR, Loosier PS, Alleman-Velez PL, Simmons J (2004). Providers’ perspectives and beliefs regarding transition to adult care for adolescents with sickle cell disease. J Health Care Poor Underserved 15(3):443-461.
105. Sears DA (1978). The morbidity of sickle cell trait: a review of the literature. Am J Med 64:1021-1036.
106. Sears DA. Sickle Cell trait. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, editors. Sickle Cell Disease: Basic Principles and Clinical Practice. New York, Raven Press, 1994: 381-394.
107. Jones SR, Binder RA, Donowho EM Jr (1970). Sudden death in sickle cell trait. N Engl J Med 282:323-325.
108. Virmani R, Burke AP, Farb A, Kark JA (1997). Causes of sudden death in young and middle aged competitive athletes. Cardiol Clin 15:439-466.
109. Gupta AK, Kirchner KA, Nicholson R, Adams III, JG, Schechter AN, Noguchi CT, Steinberg MH (1991). Effects of α-thalassemia and sickle polymerization tendency on the urine-concentrating defect of individuals with sickle cell trait. J Clin Invest 88:1963-1968.
110. Statius van Eps LW, de Jong PE. Sickle Cell Disease. In: Schrier RW, Gottschalk CW, editors. Disease of the Kidney, 6th edition, Vol. 1, 1997: 2201-2219.
111. Davis CJ Jr, Mostofi FK, Sesterhenn IA (1995). Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol 19:1-11.